{
    "clinical_study": {
        "@rank": "52003", 
        "arm_group": [
            {
                "arm_group_label": "Bilanced group", 
                "arm_group_type": "Experimental", 
                "description": "Sevofluorane adjusted to obtain an Et-Sevo of 1.8-2%, for all the time of the surgical procedure.\nRemifentanyl TCI adjusted according to protocol to maintain the range of 1-3 ng / ml."
            }, 
            {
                "arm_group_label": "TCI group", 
                "arm_group_type": "Active Comparator", 
                "description": "Propofol 3-4 mg / ml and remifentanyl 1-3 ng / ml according to protocol TCI"
            }
        ], 
        "brief_summary": {
            "textblock": "This study aimed to evaluate the possible protective effect of anesthetic technique balanced\n      (BAL) compared to total intravenous anesthetic technique (TIVA-TCI) in ischemia reperfusion\n      injury in microvascular flap in plastic surgery. The investigators will evaluate the\n      viability of the flap using tissue oximetry monitoring and the level of biochemical markers\n      in a circle at the end of the intervention."
        }, 
        "brief_title": "Sevoflurane Protective Effect on Ischemia Reperfusion Injury in Microvascular Surgery", 
        "condition": "Microvascular Breast Flap in Plastic Surgery", 
        "condition_browse": {
            "mesh_term": "Reperfusion Injury"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  age > 18 yr\n\n          -  ASA (American Society of Anesthesiology) I-II\n\n        Exclusion Criteria:\n\n          -  Known unusual reaction to anesthetic drugs\n\n          -  Evaluation of anesthesia increased risk for malignant hyperthermia.\n\n          -  History of vascular disease.\n\n          -  History of bleeding diathesis.\n\n          -  Tabagism"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "128", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01972230", 
            "org_study_id": "17713", 
            "secondary_id": "Claudia"
        }, 
        "intervention": [
            {
                "arm_group_label": "Bilanced group", 
                "intervention_name": "Sevoflurane", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "TCI group", 
                "intervention_name": "Diprivan + Remifentanil TCI", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Propofol", 
                "Remifentanil", 
                "Sevoflurane"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 4, 2013", 
        "location": {
            "contact": {
                "email": "forastiere@ifo.it", 
                "last_name": "Forastiere Ester", 
                "phone": "00390652662994"
            }, 
            "facility": {
                "address": {
                    "city": "Rome", 
                    "country": "Italy", 
                    "state": "RM", 
                    "zip": "00144"
                }, 
                "name": "Regina Elena Cancer Institute"
            }, 
            "investigator": {
                "last_name": "Claudia Claroni, MD", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "falciof@ifo.it", 
            "last_name": "federica falcioni", 
            "phone": "00390652665353"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "tissutal oximetry average value of the flap measured with  INVOS (In Vivo Optical Spectroscopy) system continuously.", 
            "safety_issue": "No", 
            "time_frame": "24 hours from the end of intervention"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01972230"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Regina Elena Cancer Institute", 
            "investigator_full_name": "Ester Forastiere", 
            "investigator_title": "director", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Regina Elena Cancer Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Regina Elena Cancer Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}